A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

NCT07226895 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Clinical High Risk for Psychosis (CHR)

Interventions

DRUG: MT1988 Low Dose
DRUG: MT1988 High Dose
DRUG: Placebo

Sponsor

Monument Therapeutics Limited

Collaborators

[object Object]
[object Object]
[object Object]